• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/12/25 4:08:33 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    8-K
    0001761918false00017619182025-08-122025-08-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 12, 2025

     

     

    Erasca, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40602

    83-1217027

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3115 Merryfield Row

    Suite 300

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 465-6511

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    ERAS

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 12, 2025, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit Description

    99.1 Press Release issued August 12, 2025

    104 Cover Page Interactive Data File


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Erasca, Inc.

     

     

     

     

    Date:

    August 12, 2025

    By:

    /s/ Ebun Garner

     

     

     

    Ebun Garner, General Counsel

     


    Get the next $ERAS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    1/5/2024$11.00 → $6.00Buy → Neutral
    BofA Securities
    10/11/2023$10.00Buy
    H.C. Wainwright
    3/30/2023$9.00Buy
    Mizuho
    2/24/2023$10.00Buy
    Goldman
    More analyst ratings

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Varney Michael David

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:28:03 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Liu Jean I

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:27:26 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hambleton Julie

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:27:06 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    5/22/24 6:57:45 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/8/23 9:10:12 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/6/23 7:41:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Erasca Inc.

    SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)

    8/13/25 8:14:21 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Erasca Inc.

    S-3 - Erasca, Inc. (0001761918) (Filer)

    8/12/25 4:45:10 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Erasca Inc.

    10-Q - Erasca, Inc. (0001761918) (Filer)

    8/12/25 4:27:06 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Erasca downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Erasca from Overweight to Equal-Weight and set a new price target of $2.00

    8/18/25 8:49:16 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Erasca with a new price target

    Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00

    3/26/25 7:49:37 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Erasca with a new price target

    Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

    11/18/24 7:43:18 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca Reports Second Quarter 2025 Business Updates and Financial Results

    Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended June 30, 2025.

    8/12/25 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

    Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patie

    6/2/25 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    4/27/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    1/18/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Financials

    Live finance-specific insights

    View All

    Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    5/16/24 8:02:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports First Quarter 2024 Business Updates and Financial Results

    Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

    5/8/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

    3/27/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Erasca Inc.

    SC 13G - Erasca, Inc. (0001761918) (Subject)

    11/14/24 1:28:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care